Add Company
Join Now

ConSynance Therapeutics Revenue and Competitors

License our Company Data API

Rensselaer, NY

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ConSynance Therapeutics's estimated annual revenue is currently $620k per year.(i)
  • ConSynance Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • ConSynance Therapeutics has 4 Employees.(i)
  • ConSynance Therapeutics grew their employee count by -20% last year.

ConSynance Therapeutics's People

NameTitleEmail/Phone
1
CEO and FounderReveal Email/Phone
2
Research DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is ConSynance Therapeutics?

ConSynance Therapeutics is a clinical-stage, biopharma company focused on rare central nervous system diseases. ConSynance’s lead candidate, CSTI-500 (aka BMS-866949), is a Phase II ready, best-in-class Triple Monoamine Reuptake Inhibitor for Prader-Willi Syndrome, a rare genetic neurodevelopmental disorder. To learn about Prader-Willi Syndrome, please visit www.FPWR.org. Our 2nd candidate, CSTI-100, is a Phase II ready, first-in-class, Melanin-Concentrating-Hormone Receptor 1 (“MCHR1”) inhibitor for PWS as well as for Non Alcoholic Steatohepatitis (NASH).

keywords:N/A

N/A

Total Funding

4

Number of Employees

$620k

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M10-9%N/A
#2
$1.2M1427%N/A
#3
$1.6M1525%N/A
#4
$3.1M18-44%N/A
#5
$4.5M26-10%N/A